AmpC hyperproduction in a Cedecea davisae implant-associated bone infection during treatment: a case report and therapeutic implications.

Publication

AmpC hyperproduction in a Cedecea davisae implant-associated bone infection during treatment: a case report and therapeutic implications.

Journal Paper/Review - Jan 6, 2022

Notter Julia, Seiffert Salome N, Zimmermann-Kogadeeva Maria, Bösch Anja, Wenger Robert, Strahm Carol, Frischknecht Manuel, Livermore David M, Babouee Flury Baharak

Citation

Notter J, Seiffert S, Zimmermann-Kogadeeva M, Bösch A, Wenger R, Strahm C, Frischknecht M, Livermore D, Babouee Flury B. AmpC hyperproduction in a Cedecea davisae implant-associated bone infection during treatment: a case report and therapeutic implications. BMC Infect Dis 2022; 22:33.

Type

Journal Paper/Review (English)

Journal

BMC Infect Dis 2022; 22

Publication Date

Jan 6, 2022

Issn Electronic

1471-2334

Brief description/objective

Data on antimicrobial resistance mechanisms are scanty for Cedecea spp., with very variable antibiotic resistance patterns documented. Here we report the first in vivo resistance evolution of a C. davisae clinical isolate in a patient with a complex hand trauma and provide insight in the resistance mechanism, leading to therapeutic implications for this pathogen.